The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Scheinberg David A since 2006.
The trader's CIK number is 1250316.
At the time of the last reporting, Scheinberg David A was the Director of Progenics Pharmaceuticals Inc. (stock ticker symbol PGNX).
Also see all insider trading activities at Progenics Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | PGNX | 0 | $0 | 0 | $0 | 10,000 | $53,300 |
| 2013 | PGNX | 0 | $0 | 0 | $0 | 2,500 | $9,097 |
| 2012 | PGNX | 0 | $0 | 1,250 | $12,500 | 1,250 | $8,625 |
| 2008 | PGNX | 0 | $0 | 0 | $0 | 7,500 | $34,957 |
| 2007 | PGNX | 0 | $0 | 40,000 | $1,162,740 | 48,000 | $192,000 |
| 2006 | PGNX | 0 | $0 | 15,000 | $421,590 | 15,000 | $60,000 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-07-01 | PGNX | Option Ex | 10,000 | 5.33 | 53,300 |
| 2013-03-22 | PGNX | Option Ex | 2,500 | 3.64 | 9,097 |
| 2012-02-23 | PGNX | Option Ex | 1,250 | 6.90 | 8,625 |
| 2012-02-23 | PGNX | Sale | 1,250 | 10.00 | 12,500 |
| 2008-03-28 | PGNX | Option Ex | 7,500 | 4.66 | 34,957 |
| 2007-03-01 | PGNX | Option Ex | 10,000 | 4.00 | 40,000 |
| 2007-03-01 | PGNX | Sale | 10,000 | 25.99 | 259,890 |
| 2007-02-02 | PGNX | Option Ex | 30,000 | 4.00 | 120,000 |
| 2007-02-02 | PGNX | Sale | 30,000 | 30.09 | 902,850 |
| 2007-01-08 | PGNX | Option Ex | 8,000 | 4.00 | 32,000 |
| 2006-12-01 | PGNX | Sale | 10,000 | 27.15 | 271,490 |
| 2006-12-01 | PGNX | Option Ex | 10,000 | 4.00 | 40,000 |
| 2006-02-27 | PGNX | Option Ex | 5,000 | 4.00 | 20,000 |
| 2006-02-27 | PGNX | Sale | 5,000 | 30.02 | 150,100 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Scheinberg David A (Director of Progenics Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.